Collective Laboratory

Collective Laboratory is a biotechnology company focused on developing and commercializing innovative diagnostic tests for infectious diseases. Founded in 2021, the company aims to address unmet needs in global health by providing rapid, accurate, and affordable diagnostic solutions. Their core technology centers around a novel molecular diagnostic platform designed for point-of-care testing.

company Overview

Collective Laboratory was established to tackle the challenges of infectious disease diagnosis, particularly in resource-limited settings. The company’s mission is to empower healthcare providers with the tools they need to quickly and accurately identify infections, leading to improved patient outcomes and public health surveillance. They are headquartered in San Diego, California.

Technology Platform

Collective Laboratory’s primary innovation is a proprietary molecular diagnostic platform. This platform utilizes a unique amplification method to detect pathogens with high sensitivity and specificity. Key features of the platform include:

• Rapid Results: Tests can deliver results in under 30 minutes.
• Point-of-Care Capability: The platform is designed for use in decentralized settings, such as clinics and field locations.
• Multiplexing: The ability to detect multiple pathogens concurrently in a single test.
• Ease of Use: The system is designed to be user-friendly, requiring minimal training.

Product Pipeline

Collective Laboratory is actively developing a range of diagnostic tests targeting various infectious diseases. As of December 15, 2025, their pipeline includes:

• Respiratory Viral Panel: A test for the simultaneous detection of influenza A/B, RSV, and COVID-19. Collective Laboratory Respiratory viral Panel
• Sexually Transmitted Infection (STI) Panel: A multiplex test for common STIs,including chlamydia,gonorrhea,and trichomoniasis.
• Antimicrobial Resistance (AMR) Markers: Tests to identify genetic markers associated with antibiotic resistance.

Funding and Partnerships

Collective Laboratory has secured significant funding from venture capital firms and government grants. In November 2024, the company announced a $20 million series A funding round led by Kleiner Perkins.they have also established partnerships with several academic institutions and public health organizations to validate and deploy their technology. A key partnership with the Centers for Disease Control and Prevention (CDC) is focused on evaluating the platform for use in global disease surveillance programs.

Future Outlook

Collective Laboratory is poised for continued growth as it expands its product portfolio and geographic reach. The company plans to pursue regulatory approvals for its tests in key markets, including the United States, Europe, and Africa. They are also investing in research and development to expand the capabilities of their platform and address emerging infectious disease threats. The company’s commitment to innovation and accessibility positions it as a key player in the future of infectious disease diagnostics.

Key Takeaways

• Collective Laboratory is a biotechnology company developing rapid, point-of-care diagnostic tests.
• Their core technology is a novel molecular diagnostic platform with high sensitivity and specificity.
• The company has a growing product pipeline targeting respiratory viruses, STIs, and antimicrobial resistance.
• Significant funding and strategic partnerships support their growth and expansion.

Publication date: 2025/12/15 10:56:36